iSpecimen Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
iSpecimen Inc. (ISPC) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $312.17 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-14.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2025-04-14
- iSpecimen Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was $0.00.
- iSpecimen Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00.
- iSpecimen Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-06-30 was $0.00.
- iSpecimen Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-03-31 was $333.12K.
- iSpecimen Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $312.17K, a 87.65% increase from fiscal 2023.
- iSpecimen Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $166.36K, a 50.06% decline from fiscal 2022.
- iSpecimen Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $333.12K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2024-12-31 | $312.17K 10-K · filed 2025-04-14 | |||
| 2023-12-31 | $166.36K 10-K · filed 2024-03-13 | |||
| 2022-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 derived: sum of 3 quarters · filed 2023-03-30 | $333.12K 10-K/A · filed 2023-03-30 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $0.00 derived: sum of 2 quarters · filed 2022-11-08 | $333.12K 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $333.12K 10-Q · filed 2022-08-04 | ||
| 2022-03-31 | $333.12K 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |